A new era for transplant-ineligible R/R LBCL patients: what's changing?
2/5 보강
TL;DR
The phase II PILOT study demonstrated that liso-cel is effective in medically unfit individuals, supporting the definition of a distinct category of ASCT-ineligible patients, supporting the definition of a distinct category of ASCT-ineligible patients.
OpenAlex 토픽 ·
CAR-T cell therapy research
Lymphoma Diagnosis and Treatment
Chronic Lymphocytic Leukemia Research
The phase II PILOT study demonstrated that liso-cel is effective in medically unfit individuals, supporting the definition of a distinct category of ASCT-ineligible patients, supporting the definition
APA
Giuseppe Tarantini, Rosanna Maria Miccolis, et al. (2026). A new era for transplant-ineligible R/R LBCL patients: what's changing?. Leukemia & lymphoma, 67(5), 997-1004. https://doi.org/10.1080/10428194.2026.2636979
MLA
Giuseppe Tarantini, et al.. "A new era for transplant-ineligible R/R LBCL patients: what's changing?." Leukemia & lymphoma, vol. 67, no. 5, 2026, pp. 997-1004.
PMID
41774434 ↗
Abstract 한글 요약
Most patients with large B-cell lymphoma (LBCL) are cured with frontline chemoimmunotherapy; however, 30-40% experience relapsed or refractory (R/R) disease. Historically, salvage chemotherapy followed by autologous stem cell transplantation (ASCT) represented the standard second-line treatment. Several studies have demonstrated that patients with primary refractory or early-relapsed LBCL derive limited benefit from ASCT. With the advent of chimeric antigen receptor (CAR) T-cell therapy, the prognosis of R/R LBCL has changed substantially. The TRANSFORM and ZUMA-7 trials, which showed superior efficacy and manageable toxicity, led to the approval of lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) as second-line options. Importantly, these trials required participants to be medically fit for ASCT. This review focuses on therapeutic options for transplant-ineligible patients with R/R LBCL. The phase II PILOT study demonstrated that liso-cel is effective in medically unfit individuals, supporting the definition of a distinct category of ASCT-ineligible patients. Additional active options include antibody-drug conjugates, bispecific antibodies in combination with chemotherapy, and other novel immunotherapies, which have shown promising response rates in this difficult-to-treat population.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Immunotherapy
- Adoptive
- Lymphoma
- Large B-Cell
- Diffuse
- Salvage Therapy
- Hematopoietic Stem Cell Transplantation
- Antineoplastic Combined Chemotherapy Protocols
- Treatment Outcome
- Clinical Trials as Topic
- Combined Modality Therapy
- Neoplasm Recurrence
- Local
- CAR-T
- LBCL
- immunotherapy
- partial remission
- primary refractory
- transplant-ineligible
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.